Markets
Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma (AERI – Research Report) today and set a price target of $26.00. The company’s shares closed last Tuesday at $17.66.
According to TipRanks.com, Belanger is a 4-star analyst with an average return of 8.8% and a 49.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.
Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $27.25, implying a 47.6% upside from current levels. In a report issued on April 15, Oppenheimer also maintained a Buy rating on the stock with a $26.00 price target.
Mizuho Securities Remains a Buy on Aerie Pharma (AERI) markets.co - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from markets.co Daily Mail and Mail on Sunday newspapers.